Nautilus Biotechnology installed its single‑molecule protein analysis platform at the Buck Institute to study tau proteoforms in Alzheimer’s and other neurodegenerative diseases. Buck is the first external institution to run Nautilus instruments locally as the company prepares an early‑access program for targeted applications in H1 2026. Nautilus’ platform uses DNA‑origami functionalized chips to deposit and analyze billions of individual proteins, enabling detection of hundreds of tau proteoforms at low relative abundances. The company reported a 39% jump in its stock after announcing the Buck placement, reflecting investor enthusiasm for high‑resolution proteomics enabling new biomarker and target discovery. If broadly adopted, single‑molecule proteomics could reshape biomarker discovery, target validation and translational neuroscience by revealing proteoform‑level changes that mass spectrometry or bulk assays miss.